Fresenius takes full control of mAbxience in decisive biosimilars move

By Vivian Lin · September 30, 2026, 11:04 PM · 4 mins read

Fresenius SE & Co. KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, consolidating its grip on the biosimilars platform and setting the stage for future portfolio expansion.

Fresenius SE & Co. KGaA now owns all of mAbxience. The company bought the last 45% stake from Insud Pharma. mAbxience is now fully under the Fresenius Kabi Biopharma group. This is not a routine deal. Fresenius is making a clear push to lead in biosimilars as patents on major biologics run out.

Fresenius controls the whole mAbxience platform. That means every step, from development and manufacturing to sales, is now in its hands. The company first took a 55% stake in August 2022. That was just the start. With the final 45% now secured, Fresenius removes any doubt about costs, capacity, or launch timing. The company now gets the full financial benefit as biosimilar demand grows. A Reuters financial review confirms the deal closed on September 30, 2026. Fresenius is now the sole owner.

The total value of the deal reached up to 750 million euros, including a 50 million euro contingent payment tied to regulatory milestones at production sites.

The Fresenius and mAbxience partnership has already delivered results. They have worked together on development, manufacturing, technology transfer, and regulatory goals. The integration has boosted manufacturing and sped up technology transfer. mAbxience is now a stronger global player. Michael Sen, CEO of Fresenius, said, "Completing the acquisition of mAbxience marks the next milestone in building a leading, vertically integrated biopharma business at scale."

Jurgen van Broeck, CEO of mAbxience, stays in charge. He reports to Dr. Sang-Jin Pak, President Biopharma at Fresenius. Van Broeck credits both the mAbxience and Insud Pharma teams for the company’s progress. He calls full ownership "the natural next step" and says it creates a stronger base for innovation, growth, and long-term impact for patients, customers, and partners.

For patients, the impact is clear. Fresenius promises steady access to high-quality biosimilars. This comes at a time when drug prices and supply chains face tough questions. For shareholders, the deal is a focused investment in a business Fresenius knows well. The company can now set the pace and control the economics of future launches. A report by finanzen.ch notes the acquisition needed no extra regulatory approvals. That sped up the process and allowed for immediate integration.

mAbxience continues to serve as an operational hub for biosimilar development and manufacturing. In September 2026, the company entered a separate agreement with Sandoz for an emicizumab biosimilar candidate, with mAbxience responsible for development and production in Spain and Argentina, while Sandoz secured global commercialization rights outside select Latin American countries.

ad hoc news

mAbxience will keep supporting its current customers and partners. The company says it will maintain its focus on quality and reliable supply worldwide. Both Sen and van Broeck point to the company’s drive and scientific skill as key to the next phase of growth under Fresenius’s full control.

This deal fits a bigger pattern in biopharma. Companies are buying up rivals to build scale. Zymeworks, for example, recently bought Theravance Biopharma to change its revenue mix. But the Fresenius-mAbxience deal is all about biosimilars. This market is set to grow fast as more biologic patents expire.

Fresenius is betting big on mAbxience. The goal is clear: take a leading spot in biosimilars by using full control and a proven platform. In this sector, scale and timing matter. This deal is more than a milestone. It is a signal to rivals who are still waiting. Fresenius is moving fast.

Topics:

Biotech Investing Regulation & Biomanufacturing

Biotechnology Newsroom

Vivian Lin

Vivian Lin is Biotech Markets & Transactions Editor at GenoMethods, covering licensing agreements, M&A, biotech financing, company pipelines, strategic partnerships and cross-border transactions. Her reporting connects deal structure and company strategy with the scientific and clinical evidence underlying each biotechnology asset.